The World Health Organization reports that the recent outbreaks of hepatitis A virus (HAV) mainly affect communities of men having sex with men. We also know that people living with HIV are more likely to suffer from prolonged symptoms and consequences of a HAV infection. Contrary to popular belief, HAV affects large groups of the population, and the possible vectors of infection and risks are generally underestimated. While there is effective immunisation available against hepatitis A, this is not always actively sought by the persons who need it. There has also been some discussion about the pricing of and access to HAV vaccine across Europe with some shortages and delays reported.
Date and time: 28 August 2017, 15:00 CET
Click here to register: https://www.surveymonkey.de/r/T6Z3TPZ
Registration closes: Friday, 25 August 2017, 16:00
Speaker: Prof. Jürgen Rockstroh
Jürgen Rockstroh, MD, is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany. In addition to his clinical practice, Dr Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. From 2007-2011 he was the president of the German AIDS Society. He is also since 2009 a member of the executive committee of the European AIDS Clinical Society (EACS) and since 2011 member of the governing council of the International AIDS Society. In 2015 Professor Rockstroh was elected chair of HIV in Europe. In 2016, he was elected as president-elect of EACS.
Download a flyer about the webinar here: